Macroeconomic effects of the response to HIV: Defining the path to long run impact analysis XVII International AIDS Conference Mexico, 5 August 2008 E.

Slides:



Advertisements
Similar presentations
IMPACT OF HIV/AIDS ON DEVELOPMENT. EVOLUTION OF HIV/AIDS Incidence of the disease adding to the disease burden measure. Sero- prevalence found in the.
Advertisements

The Economic Impact of HIV/AIDS Shanta Devarajan.
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA,
Brazzaville, Congo 5-7 March 2014
Assessment of PEPFAR’s Impact on Selected Health System Parameters in Sub-Saharan African Countries Presented by: Anya Shen Viviane D. Lima, Wendy Zhang,
Is HIV/AIDS still exceptional? Alan Whiteside Health Economics and HIV/AIDS Research Division, University of KwaZulu-Natal Durban Presentation to Daniel.
The importance of economic growth
AFRICA CAN SOLVE ITS OWN HEALTH PROBLEMS? SARALA NAICKER Division of Nephrology University of Witwatersrand Johannesburg, South Africa.
Economic Growth in Africa By Xavier Sala-i-Martin June 2004.
July 2014 Regional Data Slides. Source: UNAIDS.
Moving to the final chapter of the AIDS epidemic.
HIV and the Financial Crisis Academic Council Debate on the Financial Crisis and Public Health Robert Greener, April 30, 2009.
Overview of HIV & AIDS in Africa
Craig McClure Chief, HIV and AIDS section NYHQ Workshop on ART in Pregnancy, Breastfeeding and Beyond Johannesburg, South Africa, June 18-20, 2012 Planning.
African Economic Outlook 2003/2004 Paris, 7 July 2004.
Latin America/Caribbean State of the Art HIV/AIDS Part Deux Paul R. De Lay, M.D. Chief, HIV/AIDS Division Global Bureau USAID March 13, 2001.
Comparing HIV and AIDS Prevalence within Countries By: Dan Evans Ida Nordestgaard Lacey McLean By: Dan Evans Ida Nordestgaard Lacey McLean 30 April 2009Economic.
Disclaimer Median Real Income, Sub- Saharan Africa.
Slide 1 Bilateral Aid Review March Slide 2 Contents - Objectives of the review - The review process and methodology - Summary of key outcomes -
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
PORTFOLIO AND SELECT COMMITTEES ON FINANCE March 2006.
GAP Report 2014 People left behind: Children and pregnant women living with HIV Link with the pdf, Children and pregnant women living with HIV.
Tracking Expenditure for HIV and AIDS in Africa ~ Cross-Country Comparisons Guthrie, T., Kioko, U. Inaugural Conference of the African Health Economics.
Antiretroviral Treatment (ART) & Human resources Wim Van Damme Department of Public Health ITM, 17 October 2006.
Bell Ringer What conditions could lead to an atmosphere susceptible to genocide?
PORTFOLIO AND SELECT COMMITTEES ON FINANCE June 2006.
 aew aew.
PORTFOLIO COMMITTEE OF FINANCE March INTERNATIONAL ECONOMY.
“Time is costly”: Modelling the macro-economic impact of scaling up access to antiretroviral treatment for HIV/AIDS Jean-Paul Moatti*, Bruno Ventelou*,
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
ELECTRIFICATION FOR DEVELOPMENT C T Gaunt University of Cape Town.
HIV & AIDS FUNDING AND ECONOMIC RECESSION: A CALL FOR VISIONARY LEADERSHIP International AIDS Conference Vienna, 2010 Vailet Mukotsanjera-Kowayi: HEAD:
Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.
HIV/AIDS and Trade Presentation by Ngoni Chibukire SAfAIDS 17 Beveridge Road Avondale Harare Tel: /4.
The economic Impact of HIV/AIDS in Uganda A Workshop on Economic Epidemiology, Makerere University 3 rd -5 th August 2009 Fred Matovu, Ph.D.
Return on investment: How do whole societies benefit from improved services and coverage for key populations? Bradley Mathers Kirby Institute UNSW Australia.
The state of the national response to prevent HIV among young people: A review of national reporting in 20 high-prevalence countries I Birdthistle, S Dringus,
The State of the Epidemic in 2010 by Professor Alan Whiteside HEARD House of Lords 9 th March 2010 DFID HIV Leaders Meeting.
AIDS Epidemic Update December /06 e. AIDS Epidemic Update December /06 e TOTAL North America Eastern Europe & Central Asia Latin America.
HIV and AIDS Epidemic: Potential Contribution from DSS sites Nyovani Madise, PhD Centre for Global Health, Population, Poverty & Policy.
PEPFAR Investment Strategy (8 years of PEPFAR) Data source : OGAC Budget Total PEPFAR Investment: $21,285,918,291 Saving Lives : Changing the.
ANGLOPHONE COUNTRIES NIGERIA, GHANA, TANZANIA,ZANZIBAR, THE GAMBIA, ZIMBABWE, LESOTHO, ERITREA, ZAMBIA,RWANDA,MALAWI, KENYA, UGANDA, GREAT LAKES REGION,
Comparing HIV and AIDS Prevalence within Countries By: Dan Evans Ida Nordestgaard Lacey McLean By: Dan Evans Ida Nordestgaard Lacey McLean 30 April 2009Economic.
AFRICA HIV/AIDS AIDS DATA SOURCE: UNAIDS 2007 REPORT WORLD HEALTH ORGANIZATION.
VSO - RAISA. n Who are we? n What are our tools? n So What?
6 th Annual Emergency Plan for AIDS Relief Track 1.0 ART Program Meeting August 11–12, 2008; Washington D.C. Christian Pitter, MD MPH Director, Global.
Where services are needed The number of people (both adults and children) living with HIV who are not receiving antiretroviral therapy.
Strengthening HIV/AIDS Programs Through Multisectoral Approaches Ishrat Z. Husain USAID/Bureau for Africa Office of Sustainable Development PHN Officers’
Distribution of Number of People Infected with HIV Total = 10.7 million in 2000.
PORTFOLIO COMMITTEE ON FINANCE September INTERNATIONAL ECONOMY.
Where services are needed The number of women and girls who were newly infected with HIV in Note: For Botswana and Zimbabwe, the number of women.
The impact of HIV/AIDS on Botswana (The effects of the pandemic in our country.)
Dr Rachel Yates Senior Adviser, UNICEF HIV/AIDS section New York OWN, SCALE-UP & SUSTAIN The 16 th International Conference on AIDS & STIs in Africa 4.
Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.
What Will it Take to Reach the Fast Track Prevention Targets? July 18, 2016, International AIDS Conference Karl L. Dehne, Chief Prevention, UNAIDS.
Resource Availability for HIV, Overview of the financing situation
Somya Gupta, Reuben Granich
Njeri Kariuki United Nations Forum on Forests
Jennifer Sherwood amfAR, The Foundation for AIDS Research
The State of the Epidemic in 2010
Social protection and HIV: a corporate priority for UNAIDS
HIV/AIDS in sub-Saharan Africa July 2002
Background to GRTI Est. Nov, 1999, as a support programme to Rural Travel and Transport Programme (RTTP), a component of SSATP. Funded by Development Grant.
The Role of Donors in PPD on a Regional Level
World Health Organization
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Essential Drugs and Medicines Policy (EDM) World Health Organization
Key Affected Populations
Fifty Years of Economic Growth in Sub-Saharan Africa
2019 Progress Report launch
Presentation transcript:

Macroeconomic effects of the response to HIV: Defining the path to long run impact analysis XVII International AIDS Conference Mexico, 5 August 2008 E. Lamontagne 1, B. Ventelou 2, B. Walters 3, R. Greener 1, Y. Videau 2, E. Orgiazzi 2 With additional contributions from J.P. Moatti 2 and S. Luchini 2 1 UNAIDS, Economics and Development Analysis Unit, Geneva, Switzerland, 2 Health and Medical Research National Institute, Marseille, France, 3 University of Manchester, School of Social Sciences, Manchester, UK

Aim of the study To provide an economic model to: 1.Analyse the long term economic impact of the scaling up of HIV programmes 2.Identify economic factors that could enhance or limit its implementation

Two phases: 1.Preparation Phase (Oct 07 – June 08) –Model, variables, data 2.Development phase (Sept 08 March 09) –Definition and calibration of a long run endogenous growth model

Background HIV crisis: long wave event that superimposes on other long wave trends: –Endemic poverty –Poor governance –Health sector and other social sectors in crisis –Increasing social cost of economic transition programmes

Macroeconomic Models Previous models = the impact of the epidemic Two conclusions from previous modelling: 1.More empirical evidence is needed Behavioural effects of individuals and HH affected by HIV 2.Must be dynamic AIDS not a short-term shock but a cumulative shock

New concerns The importance of human capital in determining HIV economic impact Households and individuals are at the centre of the HIV epidemic –The source of human capital –Savings and consumption (ordinary goods or health goods) –Health status affects productivity and education attainment –Poverty and vulnerability are at individual and HH level

An augmented Solow-type model “Real production model”, oriented to long-run issues and endogenous mechanisms 1.Will not include exchange rate and monetary mechanisms Because Dutch disease effect unlikely to be generated by extra aid for HIV –Most high infection countries = limited aid dependence –Where aid for HIV is high = low aid dependence countries

Augmented Solow model to include (cont.) 2. Dealing not only with health but with healthcare access and cons => a multiple factor production function for health H = H ( G i, G H ) Where: G i : healthcare infrastructures and medical staff (health sector support) G H : HIV-related medical goods (treatment and care) Cross elasticity : can reflect health system absorption capacity 3. A human capital function determined by education and health status To emphasize the positive relation : health and economic growth Translate the OVC component

Augmented Solow model to include (cont.) 4. The economic outcome of prevention activities Challenges: How to model the infections averted by prevention activities? How to estimate the economic returns of prevention activities ? Outcomes interact at different time periods Possibilities under discussion: Might try to integrate an epidemiological model to estimate the impact of prevention on prevalence Coefficient could be built on cost effectiveness values from existing literature

The response to HIV and economic growth short term horizon 2/ ARV treatment Better health status Better mental and physical capacities Drop in sickness leave Decrease of MTCT Increase of life expectancy Better annual productivity per worker Better hourly productivity per worker Increase of the labour market participation rate Better productivity per capita 3/ Prevention Lower transmission Better career productivity 1/ Support to health sctr (facilities, human resources) Absorptive capacity constraint

The response to HIV and economic growth medium term horizon 2/ ARV treatment Better health status Better mental and physical capacities Drop in sickness leave Decrease of MTCT Drop in infant mortality Increase of life expectancy Better annual productivity per worker Better hourly productivity per worker Increase of the labour market participation rate Better productivity per capita Economic growth 3/ Prevention Lower HIV incidence Lower transmission Saving and education investment Better career productivity 1/ support to health sctr (facilities, human resources) Absorptive capacity constraint Non HIV+ people

The response to HIV and economic growth long term horizon 2/ ARV treatment Better health status Better mental and physical capacities Drop in sickness leave Decrease of MTCT Drop in infant mortality Increase of life expectancy Better annual productivity per worker Better hourly productivity per worker Increase of the labour market participation rate Better productivity per capita Economic growth 3/ Prevention & VAW Lower HIV incidence Lower transmission Saving and education investment Better career productivity 1/ support to health sctr (facilities, human resources) Absorptive capacity constraint Non HIV+ people 4/ OVC

Conclusion The new proposed model will: Take into consideration the endogenous impact of the epidemic on the behaviour of individuals and HH Enable to translate the long term impact of different HIV programmes on these behaviours: –elasticity of GDP to alternative combinations of HIV activities Enable selection and analysis of economic added value of National HIV Programmes

Thank you

Macroeconomic effects of the response to HIV: Defining the path to long run impact analysis Contact person: Erik Lamontagne E. Lamontagne 1, B. Ventelou 2, B. Walters 3, R. Greener 1, Y. Videau 2, E. Orgiazzi 2 With additional contributions from J.P. Moatti 2 and S. Luchini 2 1 UNAIDS, Economics and Development Analysis Unit, Geneva, Switzerland, 2 Health and Medical Research National Institute, Marseille, France, 3 University of Manchester, School of Social Sciences, Manchester, UK

Annexes Dutch Disease Effect and aid dependence

Annex 1 : Aid Dependence (net aid flows to GDP) in % Year Country/Group Botswana Central African rep Cote d'Ivoire Gabon Haiti Kenya Lesotho Malawi Mozambique Namibia South Africa Swaziland Tanzania Uganda Zambia Zimbabwe World Development Indicators (April 2007)

Annex 2: commitments for HIV/AIDS as a proportion of total commitments from all sources (in %) Year Botswana Central African Rep Cote d'Ivoire Gabon Haiti Kenya Lesotho Malawi Mozambique Namibia South Africa Swaziland Tanzania Uganda Zambia Zimbabwe Source: OECD DAC database (2007)

Data The model will be calibrated for 5 -7 countries Using country specific data Parameter from the literature